PATIENT REPORTED OUTCOMES OF UPADACITINIB: RESULTS FROM BIOLOGIC INADEQUATE RESPONDERS (SELECT BEYOND PHASE III TRIAL)

被引：0
|
作者：
Strand, V. [1 ]
Schiff, M. [2 ]
Tundia, N. [3 ]
Friedman, A. [3 ]
Meerwein, S. [3 ]
Pangan, A. [3 ]
Ganguli, A. [3 ]
Fuldeore, M. [3 ]
Song, Y. [4 ]
Pope, J. [5 ]
机构：
[1] Stanford Univ, Palo Alto, CA 94304 USA
[2] Univ Colorado, Denver, CO 80202 USA
[3] AbbVie Inc, N Chicago, IL USA
[4] Anal Grp Inc, Boston, MA USA
[5] Univ Western Ontario, London, ON, Canada
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷
关键词：
D O I：
10.1136/annrheumdis-2018-eular.1254
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT0255
引用
收藏
页码：990 / 990
页数：1
相关论文
共 50 条
  • [31] Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1
    Vibeke Strand
    Philip J. Mease
    Enrique R. Soriano
    Mitsumasa Kishimoto
    Carlo Salvarani
    Christopher D. Saffore
    Patrick Zueger
    Erin McDearmon-Blondell
    Koji Kato
    Dafna D. Gladman
    Rheumatology and Therapy, 2021, 8 : 1789 - 1808
  • [32] P171 Efficacy and safety of upadacitinib in patients with active PsA and inadequate response to biologic DMARDs (SELECT-PsA-2): a double-blind, randomised controlled Phase III trial
    Genovese, Mark C.
    Lertratanakul, Apinya
    Anderson, Jaclyn
    Papp, Kim
    Tillett, William
    van den Bosch, Filip
    Tsuji, Shigeyoshi
    Dokoupilova, Eva
    Keiserman, Mauro
    Wang, Xin
    Zhong, Sheng
    Zueger, Patrick
    Pangan, Aileen
    Mease, Philip
    RHEUMATOLOGY, 2021, 60
  • [33] Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT (vol 21, 272, 2019)
    Strand, Vibeke
    Pope, Janet
    Tundia, Namita
    Friedman, Alan
    Camp, Heidi S.
    Pangan, Aileen
    Ganguli, Arijit
    Fuldeore, Mahesh
    Goldschmidt, Debbie
    Schiff, Michael
    ARTHRITIS RESEARCH & THERAPY, 2020, 22 (01)
  • [34] The patient's perspective on treatment with dacomitinib: patient-reported outcomes from the Phase III trial ARCHER 1050
    Paty, Jean
    Sandin, Rickard
    Reisman, Arlene
    Wu, Yi-Long
    Migliorino, Maria Rita
    Zhou, Xiangdong
    Cheng, Ying
    Lee, Ki Hyeong
    Nakagawa, Kazuhiko
    Niho, Seiji
    Corral, Jesus
    Pluzanski, Adam
    Linke, Rolf
    Meyers, Oren
    Mok, Tony S.
    FUTURE ONCOLOGY, 2021, 17 (07) : 783 - 794
  • [35] Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond
    Strand, Vibeke
    de Vlam, Kurt
    Covarrubias-Cobos, Jose A.
    Mease, Philip J.
    Gladman, Dafna D.
    Chen, Linda
    Kudlacz, Elizabeth
    Wu, Joseph
    Cappelleri, Joseph C.
    Hendrikx, Thijs
    Hsu, Ming-Ann
    RMD OPEN, 2019, 5 (01):
  • [36] Patient-Reported Outcomes in Psoriatic Arthritis Patients with an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: SELECT-PsA 2
    Vibeke Strand
    Filip Van den Bosch
    Roberto Ranza
    Ying-Ying Leung
    Edit Drescher
    Patrick Zueger
    Christopher D. Saffore
    Apinya Lertratanakul
    Ralph Lippe
    Peter Nash
    Rheumatology and Therapy, 2021, 8 : 1827 - 1844
  • [37] Patient-Reported Outcomes in Psoriatic Arthritis Patients with an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: SELECT-PsA 2
    Strand, Vibeke
    Van den Bosch, Filip
    Ranza, Roberto
    Leung, Ying-Ying
    Drescher, Edit
    Zueger, Patrick
    Saffore, Christopher D.
    Lertratanakul, Apinya
    Lippe, Ralph
    Nash, Peter
    RHEUMATOLOGY AND THERAPY, 2021, 8 (04) : 1827 - 1844
  • [38] Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial
    Vinik, Aaron
    Bottomley, Andrew
    Korytowsky, Beata
    Bang, Yung-Jue
    Raoul, Jean-Luc
    Valle, Juan W.
    Metrakos, Peter
    Hoersch, Dieter
    Mundayat, Rajiv
    Reisman, Arlene
    Wang, Zhixiao
    Chao, Richard C.
    Raymond, Eric
    TARGETED ONCOLOGY, 2016, 11 (06) : 815 - 824
  • [39] Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial
    Aaron Vinik
    Andrew Bottomley
    Beata Korytowsky
    Yung-Jue Bang
    Jean-Luc Raoul
    Juan W. Valle
    Peter Metrakos
    Dieter Hörsch
    Rajiv Mundayat
    Arlene Reisman
    Zhixiao Wang
    Richard C. Chao
    Eric Raymond
    Targeted Oncology, 2016, 11 : 815 - 824
  • [40] Impact of adalimumab treatment on patient-reported outcomes: Results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis
    Revicki, Dennis A.
    Willian, Mary Kaye
    Menter, Alan
    Gordon, Kenneth B.
    Kimball, Alexa B.
    Leonardi, Craig L.
    Langley, Richard G.
    Kimel, Miriam
    Okun, Martin
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2007, 18 (06) : 341 - 350
12345